Evaluation and Management of Scalp Hair Loss

Clinical Diagnosis

• The diagnosis of alopecia areata can be made clinically without laboratory testing in most cases, and intralesional triamcinolone acetonide injections are the first-line treatment if intervention is desired, according to the British Journal of Dermatology 1, 2
• Key diagnostic features include round or oval patches of complete hair loss on the scalp, short broken hairs with tapered ends, slightly reddened skin, and yellow dots visible on dermoscopy, as noted by the British Journal of Dermatology 1, 3, 4
• Nail involvement occurs in approximately 10% of cases, as reported by the British Journal of Dermatology 3

Differential Diagnosis to Exclude

• Trichotillomania, tinea capitis, telogen effluvium, systemic lupus erythematosus, and secondary syphilis should be considered as alternative diagnoses, according to the British Journal of Dermatology 1, 3, 4

Laboratory Testing

• Investigations are unnecessary in most cases of alopecia areata, but may be considered when the diagnosis is in doubt, as stated by the British Journal of Dermatology 1, 4, 5
• Appropriate tests may include fungal culture, skin biopsy, serology for lupus erythematosus, or serology for syphilis, as recommended by the British Journal of Dermatology 1, 4, 5

Treatment Approach

• Reassurance alone is a legitimate first approach for limited patchy hair loss of short duration, with spontaneous remission occurring in up to 80% of patients, according to Praxis Medical Insights 2, 6
• Intralesional triamcinolone acetonide injections achieve 62% full regrowth rates in patients with fewer than five patches less than 3 cm in diameter, as reported by Praxis Medical Insights 2, 6
• Topical minoxidil 5% can be added as adjunctive therapy, but should not be used as monotherapy for alopecia areata, as noted by Praxis Medical Insights 2

Prognosis

• Disease severity at presentation is the strongest predictor of long-term outcome, with 68% of patients with less than 25% hair loss initially reporting being free of disease at follow-up, as reported by the British Journal of Dermatology 1, 4
• Hair follicles are preserved in alopecia areata, and the potential for recovery of hair growth is maintained, even in longstanding disease, according to the British Journal of Dermatology 3

Psychosocial Support

• Addressing the psychological impact of hair loss is important, as patients may feel self-conscious, conspicuous, angry, rejected, or embarrassed, as noted by the British Journal of Dermatology 1, 4, 5

Topical Corticosteroid Treatment for Alopecia Areata

Introduction to Treatment

• The British Association of Dermatologists recommends clobetasol propionate 0.05% as the topical corticosteroid for scalp alopecia areata, although evidence for topical steroids remains limited 7

Treatment Selection and Application

• For limited patchy hair loss, reassurance alone is legitimate as spontaneous remission occurs in up to 80% of patients with short duration and limited scalp involvement 7, 8
• Active treatment should be reserved for patients who desire intervention or have cosmetically significant disease 7
• Apply clobetasol propionate 0.05% foam or cream twice daily to affected areas 7

Expected Efficacy and Outcomes

• Clobetasol propionate 0.05% foam achieved ≥50% hair regrowth in 21% of treated sites versus 3% with placebo at 12 weeks 7, 9
• The British Association of Dermatologists notes that very potent topical steroids are widely used to treat alopecia areata but the evidence for their effectiveness is limited 7

Adverse Effects and Monitoring

• Folliculitis is the most common side-effect of potent topical steroids 7, 10, 11
• Patients should be forewarned about high relapse rates even with initially successful treatment 7, 12

Treatment of Alopecia Areata

Introduction to Treatment Options

• The British Association of Dermatologists assigns a "Strength of recommendation C, Quality of evidence III" rating to the evidence for topical corticosteroids in alopecia areata, indicating limited evidence 13

Evidence for Topical Corticosteroids

• A randomized controlled trial of 0.25% desoximetasone cream in 70 patients failed to show significant benefit over placebo, according to the British Association of Dermatologists 13

Considerations for Treatment

• No treatment has been shown to alter the long-term course of alopecia areata; all interventions only induce temporary hair growth, as stated by the British Association of Dermatologists 13
• The prognosis in long-standing extensive alopecia is usually poor, with high failure rates for all treatments, according to the British Association of Dermatologists 13

Intralesional Corticosteroids as Alternative Treatment

• Intralesional triamcinolone acetonide injections achieve 62% full regrowth rates in patients with fewer than five patches less than 3 cm in diameter, as reported by the British Association of Dermatologists 13
• Monthly injections of intralesional triamcinolone acetonide should be repeated until satisfactory response is obtained, as recommended by the British Association of Dermatologists 13

Intralesional Steroids for Hair Loss Conditions

Introduction to Hair Loss Treatment

• The British Journal of Dermatology recommends intralesional corticosteroids for alopecia areata, not androgenic alopecia, as the therapeutic mechanism addresses autoimmune inflammation in alopecia areata 14

Critical Distinction Between Hair Loss Types

• The evidence provided exclusively addresses alopecia areata, an autoimmune condition causing patchy hair loss, which is a fundamentally different disease from androgenic alopecia, a genetic/hormonal pattern baldness 14

Diagnosis and Evidence‑Based Management of Patchy Alopecia Areata

Clinical Diagnosis

• Alopecia areata can be diagnosed clinically without laboratory testing by identifying round or oval patches of complete hair loss, short “exclamation‑mark” hairs at the margins, slightly reddened but otherwise normal‑appearing skin, and yellow dots on dermoscopy. 15
• Nail involvement (pitting or ridging) occurs in about 10 % of cases. 15
• Important conditions to exclude include trichotillomania, tinea capitis, telogen effluvium, systemic lupus erythematosus, and secondary syphilis. 15

When Laboratory Tests Are Indicated

• Skin biopsy is recommended when early scarring alopecia is a concern. 15

Initial (Non‑Interventional) Management

• For limited patchy disease of short duration (< 1 year), reassurance without active treatment is the evidence‑based first‑line approach because spontaneous remission occurs in up to 80 % of patients with a small number of circumscribed patches. 15
• Between 34 % and 50 % of patients achieve spontaneous remission within one year. 15
• Hair follicles remain preserved, maintaining the potential for regrowth even in longstanding disease. 15

Active Treatment – First‑Line Intralesional Therapy

• Intralesional triamcinolone acetonide (5–10 mg/mL) is the first‑line pharmacologic therapy, supported by the strongest evidence (Strength B, Quality III). 15
• In patients with up to five small patches (each < 3 cm), full regrowth is achieved in approximately 62 % of cases. 15
• The therapeutic effect typically lasts about 9 months, after which maintenance injections are often required. 15
• Skin atrophy at injection sites is a consistent adverse effect. 15

Second‑Line Topical Corticosteroids

• Potent topical steroids such as clobetasol propionate 0.05 % foam or cream applied twice daily are a second‑line option, but the evidence is limited (Strength C, Quality III). 15
• ≥50 % hair regrowth was observed in 21 % of treated sites versus 3 % with placebo after 12 weeks. 15
• Folliculitis is the most common side effect of topical corticosteroid therapy. 15

Adjunctive Therapy

• Topical minoxidil 5 % may be added to intralesional or topical steroid regimens, but it should not be used as monotherapy for alopecia areata. 15

Limitations of Treatment

• No current therapy has been shown to modify the long‑term course of alopecia areata; all interventions provide only temporary hair growth and are associated with high relapse rates. 15

Prognostic Counseling

• Disease severity at presentation is the strongest predictor of outcome: 68 % of individuals with < 25 % scalp hair loss become disease‑free, compared with only 8 % of those with > 50 % loss. 15
• Nearly all patients experience more than one disease episode. 15
• Between 14 % and 25 % progress to alopecia totalis or universalis, and full recovery in these cases is uncommon (< 10 %). 15